FDA approves sixth drug for Biogen Idec; Plegridy will be made in Morrisville

08/18/2014 3:33 PM

08/18/2014 4:14 PM

Federal regulators approved a sixth drug for sale in the United States by Biogen Idec, a Massachusetts drug developer that plans to make all six medications in the Triangle within a year.

Biogen said Friday its Multiple Sclerosis drug, Plegridy, was approved as a new treatment to help prevent MS relapses. The drug is an interferon with a mechanism that extends its effectiveness so that injections can be reduced by half to once every two weeks.

Plegridy is Biogen’s third drug approved for the U.S. market this year by the U.S. Food and Drug Administration. FDA approval was based on a study using more than 1,500 MS patients, more than a third of whom saw a significant reduction of relapses using the Biogen treatment, the company said.

Cambridge, Mass.-based Biogen employs 7,000 globally, including 1,100 in Morrisville and 100 in Durham.

The company’s approved drugs are used by MS and hemophilia patients.

Plegridy can be injected at a doctor’s office or at home using a pre-filled, syringe called a “Plegridy Pen.”

Join the Discussion

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Terms of Service